Skip to main content
Premium Trial:

Request an Annual Quote

IonGate Raises $1.4M to Expand US Business

NEW YORK (GenomeWeb News) – IonGate Biosciences said today that it has raised €1 million ($1.4 million) in a new round of private funding from Hessen Kapital I.
 
The Frankfurt, Germany-based firm said that it would use the funds to expand its business in the US and increase global commercialization of its SURFE2R technology. IonGate recently launched its SURFE2R Workstation 5000 for functional screening of transporters in higher-throughput pharmaceutical discovery and development.
 
Earlier this year, IonGate raised €4.6 million ($6.8 million) in a third round of private financing with investors Heidelberg Innovation and Kreditanstalt für Wiederaufbau. The firm also established a New York-based subsidiary to help marketing efforts for the SURFE2R platform.
 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.